• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Systematic treatment in unresectable hepatocellular carcinoma: The most concerns.不可切除肝细胞癌的系统治疗：最受关注的问题。
ILIVER. 2024 Aug 13;3(3):100112. doi: 10.1016/j.iliver.2024.100112. eCollection 2024 Sep.
2
External beam radiotherapy for unresectable hepatocellular carcinoma.不可切除肝细胞癌的外照射放疗
Cochrane Database Syst Rev. 2017 Mar 7;3(3):CD011314. doi: 10.1002/14651858.CD011314.pub2.
3
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.钇-90微球放射性栓塞治疗不可切除的肝细胞癌
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
4
Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.早期和极早期肝细胞癌的消融和非手术治疗：系统评价和网络荟萃分析。
Health Technol Assess. 2023 Dec;27(29):1-172. doi: 10.3310/GK5221.
5
Tamoxifen for adults with hepatocellular carcinoma.他莫昔芬治疗肝细胞癌成人患者。
Cochrane Database Syst Rev. 2024 Aug 12;8(8):CD014869. doi: 10.1002/14651858.CD014869.pub2.
6
Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis.免疫治疗或靶向治疗作为不可切除肝细胞癌的一线策略：一项网络荟萃分析和成本效益分析。
Front Immunol. 2023 Jan 11;13:1103055. doi: 10.3389/fimmu.2022.1103055. eCollection 2022.
7
Lenvatinib in the treatment of unresectable hepatocellular carcinoma: a systematic review of economic evaluations.仑伐替尼治疗不可切除肝细胞癌的经济学评价系统综述。
Eur J Clin Pharmacol. 2023 Jul;79(7):885-895. doi: 10.1007/s00228-023-03502-7. Epub 2023 May 19.
8
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.经动脉化疗栓塞联合索拉非尼治疗不可切除肝细胞癌的系统评价与Meta分析
BMC Gastroenterol. 2018 Sep 4;18(1):138. doi: 10.1186/s12876-018-0849-0.
9
Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.经动脉化疗栓塞术联合阿帕替尼治疗不可切除肝细胞癌：一项多中心、随机、开放标签的III期试验
BMC Med. 2025 May 28;23(1):313. doi: 10.1186/s12916-025-04159-y.
10
Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma-a multicentric study.阿替利珠单抗/贝伐珠单抗治疗不可切除肝细胞癌的安全性和有效性——一项多中心研究
BMC Cancer. 2025 Jul 1;25(1):1026. doi: 10.1186/s12885-025-14400-9.

本文引用的文献

1
Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions.肝细胞癌根治性治疗后的辅助治疗：几个未解决的问题。
J Clin Transl Hepatol. 2024 May 28;12(5):525-533. doi: 10.14218/JCTH.2024.00030. Epub 2024 Apr 24.
2
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.免疫检查点抑制剂和抗血管内皮生长因子抗体/酪氨酸激酶抑制剂联合或不联合经动脉化疗栓塞作为晚期肝细胞癌一线治疗方案（CHANCE2201）：一项目标试验模拟研究
EClinicalMedicine. 2024 May 6;72:102622. doi: 10.1016/j.eclinm.2024.102622. eCollection 2024 Jun.
3
Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study.不同病因肝细胞癌患者代谢综合征的患病率：一项回顾性研究
Infect Agent Cancer. 2024 May 1;19(1):21. doi: 10.1186/s13027-024-00575-6.
4
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.乐卫玛联合帕博利珠单抗对比乐卫玛联合安慰剂用于治疗晚期肝细胞癌（LEAP-002）：一项随机、双盲、III 期临床试验。
Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2.
5
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial.替雷利珠单抗对比索拉非尼用于不可切除肝细胞癌一线治疗的随机对照 3 期临床研究。
JAMA Oncol. 2023 Dec 1;9(12):1651-1659. doi: 10.1001/jamaoncol.2023.4003.
6
Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study.辅助免疫检查点抑制剂与术后肝细胞癌（PREVENT）无复发生存率的提高相关：一项前瞻性、多中心队列研究。
J Gastroenterol. 2023 Oct;58(10):1043-1054. doi: 10.1007/s00535-023-02018-2. Epub 2023 Jul 14.
7
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.纳武利尤单抗对比索拉非尼用于治疗晚期肝细胞癌（CheckMate 459）：一项随机、多中心、开放标签、III 期临床试验。
Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.

Systematic treatment in unresectable hepatocellular carcinoma: The most concerns.

作者信息

Zhong Jian-Hong, Chen Kang, Su Ze, Liu Shao-Ping, Zeng Fan-Jian, Ye Lin

机构信息

Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.

Department of Hepatobiliary Surgery, Second Affiliated Hospital of Guangxi Medical University, Nanning 530007, China.

出版信息

ILIVER. 2024 Aug 13;3(3):100112. doi: 10.1016/j.iliver.2024.100112. eCollection 2024 Sep.

DOI:10.1016/j.iliver.2024.100112
PMID:40636090
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12212649/
Abstract
摘要